Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 7Phase 1/2 7Phase 1 6Phase 4 2Phase EARLY_PHASE1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 5Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Arthritis, Rheumatoid 2Waldenstrom Macroglobulinemia 1Sjogren's Syndrome 1Neoplasm, Residual 1Mediastinal Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, B-Cell 1Leukemia 1Heart Failure 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1

Interventions

Dexamethasone 8Oxycodone 6Epoetin Alfa 5Propofol 4Palonosetron 4Meropenem 4Zoledronic Acid 3Vancomycin 3Sevoflurane 3Ondansetron 3Naloxone 3Everolimus 3Ciprofloxacin 3Cholecalciferol 3Ceftazidime 3Cefepime 3Calcium Dobesilate 3Bevacizumab 3Aspirin 3Aprepitant 3peginterferon alfa-2a 2edoxaban 2apixaban 2apatinib 2Vitamin B 12 2Vincristine 2Tobacco Use Cessation Devices 2Teicoplanin 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms × Rituximab × Clear all
NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

NCT00131313 2005-08-18

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

East Valley Hematology and Oncology Medical Group

Phase 4 Unknown
180 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡